MEDICAL POLICY DETAILS

<table>
<thead>
<tr>
<th>Medical Policy Title</th>
<th>PLUGS FOR FISTULA REPAIR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Number</td>
<td>7.01.86</td>
</tr>
<tr>
<td>Category</td>
<td>Technology Assessment</td>
</tr>
<tr>
<td>Effective Date</td>
<td>08/18/11</td>
</tr>
<tr>
<td>Revised Date</td>
<td>07/19/12, 06/20/13, 05/22/14, 04/16/15, 03/17/16, 03/16/17, 03/15/18, 02/21/19</td>
</tr>
</tbody>
</table>

Product Disclaimer

- If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
- If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit.
- If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.

POLICY STATEMENT

Based upon our criteria and assessment of peer-reviewed literature, biosynthetic fistula plugs, including plugs made of porcine small intestine submucosa or of synthetic material, have not been medically proven effective and are considered investigational for all indications including, but not limited to, the repair of anal and rectal fistulas.

POLICY GUIDELINES

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION

An anal fistula is an abnormal communication between the interior of the anal canal or rectum and the skin surface. Rarer forms may communicate with the vagina or other pelvic structures, including the bowel. Most fistulas begin as anorectal abscesses. When the abscess opens spontaneously into the anal canal (or has been opened surgically), a fistula may occur. Anal fistulas are described as low (present in the lower part and not extending up to the anorectal sling) or high (extending up to or beyond the anorectal sling). High fistula can be associated with incontinence. Anal fistulas are also classified according to their relationship with the external sphincter. Intersphincteric fistulas are the most common and cross only the internal sphincter. Transsphincteric fistulas pass through the internal and external sphincters. The type of surgical treatment depends on the location and complexity of the fistula. Treatments include fistulotomy/ fistulectomy, endorectal/anal sliding flaps, seton drain, and fibrin glue. Lay-open fistulotomy in high fistulas carries risk of incontinence. Draining setons can control sepsis but few patients heal after removal of the seton and they are poorly tolerated long term. Cutting setons can cause continence disturbances. Because of recurrence rates and the significant risk of incontinence with these surgical procedures, sphincter-preserving techniques such as fistula plugs have been evaluated and proposed as an alternative method in the treatment of anorectal fistulas.

Anal fistula plugs are biosynthetic devices used to promote healing and prevent recurrence of an anal fistula. In a minimally invasive procedure, the fistula tract is identified using a probe or imaging techniques and then cleaned by irrigation. The conical-shaped fistula plug is pulled into the tract until it blocks the internal opening and then is anchored in place with sutures. The external opening is not completely sealed so that drainage of the fistula can continue. The plug reinforces the soft tissue and then acts as a scaffold into which new tissue can grow to close the fistula. The plug is usually absorbed into the body in six (6) to eight (8) weeks. The procedure can be repeated in case of failure.

RATIONALE

The SIS Fistula Plug from Cook Biotech Incorporated received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in March 2005 based on similarity to predicate devices, including the SURGISIS® Soft Tissue Biobridge.
Graft and the STRATASIS® Urethral Sling, both manufactured by Cook Biotech Incorporated. The SIS Fistula Plug is manufactured from porcine small intestinal submucosa (SIS) and is intended for repair of anal, rectal, and enterocutaneous fistulas. The modified SIS Fistula Plug, also manufactured from porcine SIS, is supplied in a tapered configuration with a button to provide increased retention of the plug and improved blockage of the fistula. It received 510(k) clearance in October 2006. In March 2009, W.L. Gore & Associates received 510(k) clearance for the BIO-A® Fistula Plug intended for use in anorectal fistulas. The GORE BIO-A Fistula Plug device comprises a porous structure of synthetic bioabsorbable PGA/TMC copolymer fiber, degraded via a combination of hydrolytic and enzymatic pathways, the same material, technology, and three-dimensional disk with tubes mesh design as the predicate GORE Bioabsorbable Mesh hernia plug device. The indications for use and performance of the GORE BIO-A™ Fistula Plug are substantially equivalent to the predicate Cook SIS Fistula Plug.

H Ortiz and colleagues (2009) in a European trial compared use of porcine submucosal (Surgisis) anal fistula plug (AFP) with an endorectal anal flap (ERAF) procedure in a randomized controlled trial (RCT) with 43 patients who had high anal fistula. The primary endpoint was fistula healing. Recurrence was defined as the presence of an abscess in the same area or obvious evidence of fistulization. Five (5) patients in the AFP group and six (6) in the ERAF group did not receive the allocated intervention, leaving 32 patients. One (1) patient in the AFP group was lost to follow-up. A large number of recurrences in the fistula plug group led to premature closure of the trial. After one (1) year, fistula recurrence was seen in 12 of 15 patients treated with an anal fistula plug versus 2 of 16 patients who underwent the flap procedure (relative risk 6.40 [95% confidence interval 1.70-23.97]); p less than 0.001). Fistulas recurred in 9 of 16 patients who had previously undergone fistula surgery; 8 of the 9 patients had an AFP. A trend for more sphincter involvement and more females in the ERAF group was noted. Complications were not reported in this paper.

PJ van Koperen, et al. (2008) conducted a RCT to compare a fistula plug (n=31) with a mucosal advancement flap (MAF) (n=29) for the treatment of high transsphincteric fistulas. At a follow-up of 11 months, the recurrence rates were 71% (n=22) in the anal fistula plug group and 52% (n=15) in the MAF group, which was not significantly different (p=.126). There were no significant differences in postoperative pain, in pre- and postoperative incontinence scores, soiling, and quality of life. One patient in plug group and two (2) in flap group experienced postoperative complications (abscess, pain, and bleeding retrospectively).

D Christoforidis, et al. (2009) performed a retrospective analysis of patients from a U.S. center with transsphincteric fistulas treated with ERAF (n=43) or anal plug (Surgisis) (n=37) between January 1996 and April 2007. Success was defined as closed external opening in absence of symptoms at minimal follow-up of six (6) months. The success rate was 63% in the ERAF group and 32% in the in AFP group after a mean follow-up of 56 (range, 6–136) months for ERAF and 14 (range, 6–22) months. After exclusion of patients with early AFP extrusion, which may be considered a technical failure, the ERAF advantage did not meet statistical significance (p=0.06). 23 of 27 patients who had ERAF and 7 of 12 patients who had AFP responded to a questionnaire addressing functional outcomes. In the ERAF group 11 of 23 patients had no continence disturbance versus 6 of 7 in the AFP group. The lack of prospectively collected incontinence scores prior to the procedure and low response rate in the AFP group prohibit valid comparisons on functional outcomes. Complication rates were low in both groups; two (2) patients in the ERAF group required reoperation for bleeding. No serious complications occurred in the AFP group. The authors conclude that “randomized trials are needed to further elucidate the efficacy and potential functional benefit of AFP in the treatment of complex anal fistulas.”

Wang, et al. (2009) compared outcomes of all patients with transsphincteric fistulas treated with AFP from July 2005 to December 2006 (n=29) and compared them with historical controls treated with ERAF (2001–2005) (n=26). Of 26 initial flap procedures, 10 failed and 16 healed. Of 29 initial plug procedures, 19 failed and 10 healed. In total, 30 advancement flaps and 34 plug procedures were performed (including the additional treatments for failed initial procedures). Closure rates were 34% for plugs (mean follow-up 279 [range, 110–690] days) and 62% for flaps (median follow-up 819 [range, 93–1928] days; p=0.045). Complications were not reported. The authors conclude that a systematic randomized trial with long-term follow-up comparing advancement flaps with fistula plugs is needed, and they calculate that 112 patients would need to be randomized to detect a statistically significant difference in success rates for each procedure. Because the fistula plugs are costly, the authors recommend that a cost-benefit analysis be performed.

A 2010 systematic review to access the efficacy of the anal fistula plug by P Garg and colleagues reports a wide range of success rates. In the 12 included studies, all case series, reported success rates for the AFP procedure were from 24% to

Proprietary Information of Excellus Health Plan, Inc.
92%. Success rates in treating complex fistula-in-ano in the eight (8) prospective studies reviewed were 35%–87%. The authors concluded that while the anal fistula plug procedure appeared safe, further RCTs are needed.

In 2012, three (3) reviews were published comparing AFP to conventional surgical treatment for anal fistulas. Pu and colleagues undertook a meta-analysis of five (5) studies (two (2) RCTs and three (3) retrospective studies) published through April 2012. Treatment options in the conventional arm of this review included endorectal/mucosal advancement flaps, fibrin glue, and seton drains. On combined analysis, AFP patients had a higher recurrence rate (62%) compared to those undergoing conventional treatment options (47%) after three (3) months of follow-up (five (5) studies, 428 patients; p=0.004.).

Leng and Jin undertook a meta-analysis of six (6) studies published through April 2011 (three (3) RCTs, two (2) retrospective studies, and one cohort study) involving 408 patients comparing AFP with MAF. On combined analysis, the differences in the overall success rates (six (6) studies) and incidence of fistula recurrence (four (4) studies including three (3) RCTs) were not statistically significant between the AFP and MAF. The risk of continence postoperatively (three (3) studies including two (2) RCTs), however, was reported to be lower with AFP. In addition to the small numbers of controlled studies and limited follow-up, the findings of this meta-analysis were further limited by significant heterogeneity across studies.

O’Riordan and colleagues undertook a systematic review of AFP for patients with Crohn’s and non-Crohn’s-related anal fistulas. The follow-up period across studies ranged from three (3) months to 24.5 months. The pooled proportion of patients achieving fistula closure in patients with non-Crohn’s anal fistula was 0.54. The proportion achieving closure in patients with Crohn’s disease was similar. There were no reported cases of any significant change in continence after AFP insertion in any of the study patients (n=196). The findings of this systematic review are limited by the variability of operative technique and perioperative care across studies, which may influence the probability of success or failure associated with the AFP.

Overall, the evidence of efficacy of anal fistula plug treatment is limited. Two randomized controlled trials (RCTs) and retrospective comparisons did not demonstrate that anal plugs improved healing rates or reduced recurrence of anal fistulas. Numerous case series report a wide range of results (e.g., CN Ellis, et al. 2010, BJ Champagne, et al. 2006, MF McGee, et al. 2010, S Gonsalves, et al. 2009) and contribute to the inability to allow conclusions to be drawn related to the long-term efficacy of fistula plugs. RCTs with sufficient numbers of patients and with appropriate length of follow-up reporting healing and recurrence rates, and sphincter function, before and after procedures, are required.

**CODES**

- Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.
- CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.
- Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

<table>
<thead>
<tr>
<th>CPT Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code</td>
</tr>
<tr>
<td>46707 (E/I)</td>
</tr>
</tbody>
</table>

*Copyright © 2019 American Medical Association, Chicago, IL*

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code</td>
</tr>
<tr>
<td>No specific codes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD10 Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code</td>
</tr>
</tbody>
</table>

*Proprietary Information of Excellus Health Plan, Inc.*
### REFERENCES


---

**Medical Policy: PLUGS FOR FISTULA REPAIR**

**Policy Number:** 7.01.86

**Page:** 4 of 6

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J86.0</td>
<td>Pyothorax with fistula</td>
</tr>
<tr>
<td>K50.013</td>
<td>Crohn's disease of small intestine with fistula</td>
</tr>
<tr>
<td>K50.113</td>
<td>Crohn's disease of large intestine with fistula</td>
</tr>
<tr>
<td>K50.813</td>
<td>Crohn's disease of both small and large intestine with fistula</td>
</tr>
<tr>
<td>K50.913</td>
<td>Crohn's disease, unspecified, with fistula</td>
</tr>
<tr>
<td>K51.013</td>
<td>Ulcerative (chronic) pancolitis with fistula</td>
</tr>
<tr>
<td>K51.213</td>
<td>Ulcerative (chronic) proctitis with fistula</td>
</tr>
<tr>
<td>K51.313</td>
<td>Ulcerative (chronic) rectosigmoiditis with fistula</td>
</tr>
<tr>
<td>K51.413</td>
<td>Inflammatory polyps of colon with fistula</td>
</tr>
<tr>
<td>K51.513</td>
<td>Left sided colitis with fistula</td>
</tr>
<tr>
<td>K51.813</td>
<td>Other ulcerative colitis with fistula</td>
</tr>
<tr>
<td>K51.913</td>
<td>Ulcerative colitis, unspecified with fistula</td>
</tr>
<tr>
<td>K60.3-K60.5</td>
<td>Rectal anal fistula (code range)</td>
</tr>
<tr>
<td>K63.2</td>
<td>Fistula of intestine</td>
</tr>
<tr>
<td>N32.1</td>
<td>Vesicointestinal fistula</td>
</tr>
<tr>
<td>N32.2</td>
<td>Vesical fistula, not elsewhere classified</td>
</tr>
<tr>
<td>N82.2-N82.4</td>
<td>Female intestinal-genital tract fistula (code range)</td>
</tr>
</tbody>
</table>


Medical Policy: PLUGS FOR FISTULA REPAIR
Policy Number: 7.01.86
Page: 6 of 6


*Key Article

KEY WORDS

Fistula plug

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

Based upon our review, repair of an anal fistula with a fistula plug is not addressed in National or regional CMS coverage determinations or policies.